Investors, Press releases, Products GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D Day BOSTON, March 7, 2023 —GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, will today outline its pipeline strategy and R&D progress for dsRNA based crop protection and plant delivery innovations focused on addressing food security with innovative and sustainable solutions during its Plant Health R&D Day being held today, March 7th, 2023 at 10:30 a.m. ET in Research Triangle, North Carolina. “GreenLight is taking an innovative approach to advancing novel double-stranded RNA (dsRNA) solutions for numerous agricultural applications with advantages in speed of discovery/development, cost, quality and delivery. We have advanced our company’s portfolio strategy, target product profiles, and delivery capability all to meet the global challenges we face in the quest to grow food sustainably.” said Andrey Zarur, CEO of GreenLight Biosciences. “We have done this all with an eye on expanding potential addressable markets for our product portfolio and a focus on the potential benefits that our sustainable technologies could have on society.” Sustainable innovations that address emerging resistance, food security, and agricultural impacts on biodiversity As a leader in RNA innovation for agriculture, the Company is building on its existing rapid design, development and iteration capabilities for dsRNA by expanding product applications and delivery capabilities. The technological progress to be shared in today’s showcase enables GreenLight Biosciences to work towards unlocking access to the broader global insecticides and fungicides market worth $39B1,2, and the global herbicides market valued at $35.72B3. “Farmers need products that appropriately solve the challenges they face in-field, all while helping to improve the overall sustainability of agriculture,” said Mark Singleton, Chief Commercial Officer and General Manager of Plant Health. “GreenLight Biosciences is fully committed to delivering products that address some of the major challenges faced by farmers, such as increased pest resistance, tightening regulatory environments, and demands by consumers to reduce chemical loads in foods. We expect that our rapid dsRNA development and production capabilities, coupled with novel delivery technologies, will enable us to develop sustainable solutions across all crop inputs segments and help reduce agricultural impact on biodiversity.” Plant Health Strategy & Portfolio Updates Today, at GreenLight’s R&D Showcase, the Company will outline a long-term strategy to progress its Plant Health portfolio and highlight progress in its R&D pipeline that it anticipates will help farmers expand their suite of tools to preserve yield potential as threats from insects, disease, and weeds increase, including: Actively preparing for commercial launch prior to end of 2023 of our leading dsRNA solution, Calantha™, subject to regulatory approval The registration dossier for our RNA solution that targets the varroa destructor mite was submitted to the EPA in February 2023 and is now under review Expansion of dsRNA-based fungal, insecticide, and acaricide programs into multi-target applications Plant disease program data showing formulated dsRNA performance in-field providing control of grey mold and powdery mildew equivalent or better than conventional chemical standards at commercially relevant spray intervals Data demonstrating functional delivery of dsRNA into plants; showing decreased fusarium disease severity in lettuce seed treatment trials, and preliminary indications of herbicidal activity “These highlights are representative of our robust dsRNA pipeline, delivery capability and our ongoing commitment to delivering on the potential of RNA to provide farmers with the tools they need to increase productivity, profitability, and sustainability in the face of climate events and increasing resistance to conventional crop protection products,” said Zarur. “We look forward to advancing these innovations to ensure that farmers have access to technology that benefits their production, and to help create healthy people and planet through RNA innovation.” The Plant Health R&D Day is the first in a series providing comprehensive updates on GreenLight’s R&D strategy and progress. The next session will focus on the Company’s Human Health portfolio and will be hosted on Thursday, March 9th, 2023, at GreenLight Biosciences Headquarters in Lexington, MA. A copy of the presentation can be found here: Sources: 1. https://www.marketsandmarkets.com/Market-Reports/fungicides-356.html 2. https://www.marketsandmarkets.com/Market-Reports/insecticide-market-142427569.html 3. https://www.businesswire.com/news/home/20210916005897/en/Global-47.09-Bn-Herbicides-Market-to-2025-2030—ResearchAndMarkets.com About GreenLight Biosciences GreenLight Biosciences (Nasdaq: GRNA) aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. Our RNA platform allows us to research, design, and manufacture for human, animal, and plant health. In human health, this includes messenger RNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The Company’s platform is protected by numerous patents. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. Availability of Other Information About GreenLight Biosciences Investors and others should note that we communicate with our investors and the public using our website (www.greenlightbiosciences.com), the investor relations website (https://investors.greenlightbio.com/), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that GreenLight posts on these channels and websites could be deemed to be material information. As a result, GreenLight encourages investors, the media, and others interested in GreenLight to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on GreenLight’s investor relations website and may include additional social media channels. The contents of GreenLight’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Forward Looking Statements Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including those relating to the success, cost and timing of our research and development activities in our plant and human health programs, the timing of regulatory submissions and approvals, our ability to commercialize our products, the acceptance of RNA-based technologies by regulators and the public, including the timing it takes to receive regulatory approval, the success, cost and timing of our clinical trials, including estimates regarding when patients will be enrolled, when data will be reported for our ongoing clinical trials and timing to commence future clinical trials, our projected cash runway and our ability to obtain funding for our operations when needed. Forward-looking statements include statements relating to our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors included in our Quarterly Reports on Form 10-Q, periodic filings on Form 8-K, and any of our future filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by current macroeconomic conditions and the ongoing COVID-19 pandemic and there may be additional risks that we consider immaterial, or which are unknown. It is not possible to predict or identify all such risks. Our forward-looking statements only speak as of the date they are made, and we do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. For additional information on GreenLight and potential risks associated with investing, please see our public filings at https://www.sec.gov/edgar/browse/?CIK=1822691&owner=exclude. Contacts: Media Contact: Thomas CramptonSVP Corporate AffairsGreenLight Biosciences [email protected] Investor Contact: Ingrid FungDirector, Enterprise Operations and Strategy & Head of Investor Relations GreenLight Biosciences [email protected] 7 March 2023 By Jo Tang 0 Comments
Investors, Press releases, Products GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA ● GreenLight Biosciences and Queensland University of Technology (QUT) partner to create a solution for fall armyworm ● Fall armyworm is one of the most destructive insect pests on the planet, causing more than US$2 billion in annual crop loss worldwide ● The Australian government has been searching for a more environmentally-friendly solution to fall armyworm and is supporting the partnership with a AUD$400,000 grant BOSTON, MA, and BRISBANE, Australia, October 5, 2022—Researchers from Boston’s GreenLight Biosciences and the Queensland University of Technology (QUT) in Brisbane, Australia, have announced an agreement to develop a solution to fall armyworm, which causes more than US$2 billion in annual global crop loss. The partnership includes an Australian government grant to QUT of more than AUD$400,000 from the Australian Research Council. It brings together the teams of two preeminent researchers, Dr. Julia Bally and Professor Peter Waterhouse from the QUT Centre for Agriculture and the Bioeconomy, and GreenLight’s Plant Health research and development team. The partnership aims to develop a solution for fall armyworm, a pest of national priority in Australia. It is also a point of emphasis that the project delivers environmentally-friendly crop protection tools against fall armyworm. GreenLight’s plant health division is working on producing RNA-based solutions for a variety of fungi and insects that cause massive food loss and crop damage annually. In lab tests and field trials, GreenLight’s RNA-based solutions leave low or no residues. Dr. Bally said previous collaboration on fall armyworm with GreenLight had been important to securing the grant from the Australian Research Council this year. “We are excited to work with GreenLight Biosciences on this solution to armyworm,” she said. “We believe furthering our partnership will generate comprehensive new technologies to fight against one of the most damaging global crop pests and greatly improve Australian agritech capacity and strengthen international collaborations.” GreenLight’s Vice President of Plant Health R&D Ron Flannagan said: “Fall armyworm has recently invaded Australia and devastates many crops, including sorghum and cotton. Our RNA platform allows us to develop solutions faster and more efficiently than was previously possible. So we are delighted to partner with QUT to accelerate our work targeting the fall armyworm with a sustainable solution.” The project will begin with lab studies and advance to greenhouse and field trials. “We believe this research will provide significant benefits, such as added security for Australia’s most important agricultural crops and regions and global food production,” Dr. Bally said. About GreenLight Biosciences GreenLight Biosciences aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. Our RNA platform allows us to research, design, and manufacture for human, animal, and plant health. In human health, this includes messenger RNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The company’s platform is protected by numerous patents. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. GreenLight is a public benefit corporation that trades under the ticker GRNA on Nasdaq. For more information, visit https://live-greenlightbiosciences.pantheonsite.io/ Press contact: David Pesci Head of Media Relations [email protected] For press, email: [email protected] For investors, email: [email protected] 5 October 2022 By Jo Tang 0 Comments
Blog, Products 2022 GreenLight work published in peer-reviewed academic journals We will continue to update this list as more research is published throughout the year. Our team has at least three papers in the pipeline for publication this year. Novel Mobile Phase to Control Charge States and Metal Adducts in the LC/MS for mRNA Characterization Assays – American Chemical Society, 7/26/22 Editorial: New Applications of Insecticidal RNAi – Sec. Pest Management, 5/27/22 Toxicity of a novel dsRNA-based insecticide to the Colorado potato beetle in laboratory and field trials – Pest Management Science, 2/15/22 8 July 2022 By Jo Tang 0 Comments
Blog, Investors, Press releases, Products GreenLight’s June investor presentation GreenLight highlights its vision and key development pipelines in this impact deck from June. Download the full PDF below. GreenLight June investor presentationDownload 16 June 2022 By Jo Tang 0 Comments
Blog, Investors, Products International crop network validates ledprona as a new Mode of Action group An effective and novel pest-management solution with low-to-no residues aimed at the Colorado potato beetle (CPB) has received validation as a new mode of action (MoA) by the Insecticide Resistance Action Committee. Ledprona, the active ingredient in GreenLight’s CalanthaTM product, was approved as a new mode of action in the recent winter meeting of IRAC, an international association of crop-protection companies that focuses on resistance management and sustainable agriculture. The first foliar-applied, dsRNA-based bioinsecticide that provides effective control of CPB, CalanthaTM is expected to be registered in the United States this year. The Colorado potato beetle (Leptinotarsa decemlineata) ravages plants like potatoes and eggplant and accounts for more than $500 million in annual crop loss worldwide. For decades, insect resistance to pesticides has challenged growers. Using integrated pest management, which includes rotating insecticides, farmers and agronomists can prolong the useful lifespan of crop treatments. GreenLight’s product is designed to work well with standard growers’ programs to control first- and second-generation Colorado potato beetle infestations. CalanthaTM has a unique mode of action among chemical and biological insecticides, which will provide farmers with a new tool aimed at protecting potato and eggplant fields from the Colorado potato beetle and support their efforts at resistance management. Ledprona, expected to be classified as IRAC MoA group 35 (RNAi-mediated targeted suppressors), specifically targets only CPB, causing the beetle to stop eating and expire from accumulation of its own metabolic waste. Because it is based on double-stranded ribonucleic acid, CalanthaTM degrades quickly in the environment, supports biodiversity, and is an example of the next generation of eco-friendly crop-protection products. The Insecticide Resistance Action Committee helps growers around the world by developing mode-of-action classification schemes; identifying new technologies for insect, mite, and tick control products; and implementing insecticide resistance management strategies for crop protection, plant biotechnology, and public health. 5 April 2022 By Jo Tang 0 Comments
Blog, In the media, Press releases, Products ACS book chapter details GreenLight’s progress in the development of dsRNA solutions Agricultural pests are responsible for more than $100 billion in global crop losses each year. Meanwhile, the amount of arable land for farming is shrinking and traditional pesticides currently in the market are losing their efficacy. To secure a sustainable food supply for future generations, GreenLight is working on RNA-based agricultural solutions that are designed to affect the target pest and limit harm to any non-targeted organisms. In Crop Protection Products for Sustainable Agriculture, a new American Chemical Society book about crop protection innovation, a GreenLight team, led by Ken Narva and Thais Rodrigues, shares the science behind sprayable dsRNA as a new mode of action plant health product that has shown efficacy comparable to market standards and fits integrated pest management systems. This product is intended for large-acre control of the Colorado potato beetle and has been shown to be effective at extremely low use rates. A challenge to wide-scale use of dsRNA is the cost-effective production of large quantities for field applications, which GreenLight has overcome with its cell-free process to manufacture high-quality dsRNA faster, on a larger scale, and much more inexpensively than traditional methods. Successful registration of this solution will pave the way for additional dsRNA products for agricultural pest control, providing growers with biological alternatives to synthetic insecticides. 17 November 2021 By Jo Tang 0 Comments